Aadi Bioscience - WHWK Book Capitalization

WHWK (Aadi Bioscience, Inc.) - company brandmark

Aadi Bioscience Inc (WHWK) focuses on bringing targeted treatments for rare tumors to market, leveraging narrow niches with minimal competition. Current success is based on the sales of the drug FYARRO and the search for new therapeutic applications, with the indicator standing at 0.18. A monopoly position in the orphan segment shields the business from price wars. This daily price chart for Aadi Bioscience Inc (WHWK) is presented below.

WHWK Aadi Bioscience Inc Book Capitalization (03/20/2025 - 10/27/2026)

Financial and market metric breakdowns for Aadi Bio (WHWK)

- price and consensus price forecast:
Stock Quotes Aadi Bioscience Inc|WHWK - Price Target Chart
- market capitalization data:
Market Capitalization Aadi Bioscience, Inc.|WHWK - Enterprise Value
- book capitalization data:
Accounting Value per Share Aadi Bioscience|WHWK - Book Capitalization|Market Capitalization to Book Value Ratio aadibio.com|WHWK - Aggregate Company Assets
- debt and liquidity data:
Debt to Equity Ratio Aadi Bioscience Inc|WHWK - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio Aadi Bioscience Inc|WHWK - Company Aggregate Debts|Debts to Book Value Aadi Bioscience, Inc.
Summary company analysis:Aadi Bioscience - WHWK
Mass-produced product of aadibio.com

Book value capitalization reflects the net asset value minus liabilities, allowing investors to strip away market volatility and assess the actual intrinsic value of the business. Analyzing the volume of equity on the balance sheet helps determine the financial stability of Aadi Bioscience Inc (WHWK) during the market launch of the targeted drug FYARRO for the therapy of advanced oncological diseases.

Competitors of Aadi Bioscience Inc

ONC: Company Net Assets|HALO: Company Book Value|revmed.com (RVMD) - Book Capitalization|Book Capitalization AAPG|Company Net Assets CG Oncology Inc|Book Capitalization URGN|Book Capitalization BCAX (Bicara Corp)|PSNL - Company Book Value|Accounting Capitalization erasca.com ERAS|DCTH: Book Capitalization|YMAB - Company Net Assets|Book Capitalization AURA|CADL (Candel Therapeutics, Inc.) - Total Stockholders' Equity|ARAY - Company Book Value|Accounting Value of Company SELLAS Life Sciences Group Inc. (SLS)|Actuate Therapeutics (ACTU) - Company Net Assets|Accounting Value of Company Citius Oncology Inc. (CTOR)|TuHURA Biosciences - Book Capitalization|TARA - Company Net Assets|Fate Therapeutics, Inc. - Company Net Assets|TCRX: Book Capitalization|Company Book Value championsoncology.com CSBR|XBiotech (XBIT) - Accounting Value of Company|Book Capitalization CVM (CEL-SCI Corp.)|Total Stockholders' Equity OS Therapies, Inc.|Book Capitalization RADX|Book Capitalization artivabio.com (ARTV)|Book Capitalization ANL (Adlai Nortye)|Book Capitalization Veru Inc VERU|Tempest Tx (TPST) - Book Capitalization|XLO - Accounting Capitalization|renovarobio.com - Book Capitalization|Book Valuation of Business Mural Oncology|KAPA - Company Net Assets|Accounting Value of Company OnKure|Book Capitalization CytoMed Therapeutics (GDTC)|Company Book Value curis.com (CRIS)|Book Capitalization APLM|tharimmune.com - Book Valuation of Business|ADVB (Advanced Biomed Corp) - Company Book Value|GNPX: Total Stockholders' Equity|calidibio.com - Company Book Value|Sunshine Biopharma Inc. (SBFM) - Book Valuation of Business|Book Capitalization XBIO|Company Net Assets salariuspharma.com|PPBT (Purple Biotech Ltd.) - Book Capitalization|Book Valuation of Business aoncology.com (AONC)|BGNE: Book Capitalization|Checkpoint Therapeutics Inc - Total Stockholders' Equity|Elevation Oncology, Inc. (ELEV) - Company Book Value|ICAD - Accounting Capitalization|IKNA (ikenaoncology.com) - Book Capitalization|Notable Labs Ltd (NTBL) - Company Net Assets|Book Capitalization VIRX (Viracta Therapeutics Inc.)|Total Stockholders' Equity MorphoSys Corporation (MOR)|NAYA Biosciences (NAYA) - Company Net Assets|Accounting Value of Company ascentage.com (AAPGV)